Board of Directors
Scientific Advisory Board
John Bayouth, PhD, University of Wisconsin, Madison
Jeffrey Bradley, MD, Washington University, St. Louis, Missouri
Jürgen Debus, Prof. Dr., NCT Heidelberg, Germany
Carlos A. Perez, MD, Washington University, St. Louis, Missouri
Michael Steinberg, MD, University of California, Los Angeles
Vincenzo Valentini, MD, Universita Cattolica S. Cuore Roma
Hong-Gyun Wu, MD, Seoul National University Hospital, Seoul,South Korea
Mr. Moore has served as Chairman of LivaNova’s board of directors since 2015. Previously he served as a member of the board and chief executive officer of Cyberonics from 2007. Mr. Moore joined Cyberonics from Boston Scientific, where he held positions in sales, marketing and senior management in the U.S. and in Europe. His last position at Boston Scientific was president, International Distributor Management. Prior to that role, he held the position of president, Inter-Continental, a business unit of Boston Scientific. Mr. Moore earned a Bachelor of Arts from Harvard University, and a Masters of Business Administration with High Honors from Boston University.
Caley Castelein M.D.
Caley Castelein, M.D. has served as a member of our board of directors since January 2008. Dr. Castelein has served as a Managing Director of Kearny Venture Partners, L.P. since September 2006. Prior to that, Dr. Castelein served as a Managing Director at Thomas Weisel Partners, which was acquired by Stifel, Nicolaus & Company, Incorporated in July 2010, from March 2003 to September 2006. Dr. Castelein has served on the boards of directors of several private companies. Dr. Castelein holds an A.B. in Biological Sciences from Harvard College and an M.D. from the University of California, San Francisco. We believe Dr. Castelein is qualified to serve on our board of directors based on his extensive investment experience in the healthcare industry.
James F. Dempsey Ph.D.
James F. Dempsey, Ph.D. has served as our Chief Scientific Officer since founding ViewRay in March 2004. Dr. Dempsey has been a member of the board of directors since January 2008. Dr. Dempsey brings more than 17 years of experience in the field of radiotherapy medical physics to ViewRay. He previously served as a faculty member in the University of Florida Department of Radiation Oncology, as Assistant Professor from July 2001 to July 2007 and Associate Professor from July 2007 to January 2008. Dr. Dempsey holds a B.S. in Radiochemistry from San Jose State University and a Ph.D. in Nuclear Chemistry from Washington University in St. Louis. We believe Dr. Dempsey is qualified to serve on our board of directors based on his in-depth knowledge of our product, business and industry, as well as his expertise in nuclear chemistry and physics and medical physics.
Scott Drake joined ViewRay as President and CEO as of July 2018. He served as President and Chief Executive Officer of Spectranetics (NASDAQ: SPNC) from 2011 to 2017. Under Drake’s leadership, revenue grew from $117.9 million in 2010 to $245.9 million in 2015. Drake’s engineering of the 2014 acquisition of AngioScore Inc. and the 2015 acquisition of the Stellarex™ drug-coated balloon platform broadened the company’s portfolio for delivering clinical solutions for complex cardiovascular conditions and paved the way for future growth. Prior to joining Spectranetics, Drake served as Senior Vice President, Operations, of DaVita, Inc. (NYSE: DVA), a leading U.S. provider of kidney care and dialysis. His operations generated more than $6 billion of revenue, or about 20% of DaVita’s total revenue. Previously, Drake spent 17 years in several leadership positions within numerous health care business units at Covidien. From 2006 to 2009, Drake was Global Business Unit President, Respiratory and Monitoring Solutions, a $1.5 billion business with 8,000 employees. Drake was named an EY 2014 Entrepreneur Of The Year™. He is Chairman of the Boards of AtriCure (NASDAQ: ATRC) and Just Right Surgical and serves on the board of directors of the Medical Device Manufacturers Association (MDMA). He earned a BS in Business Administration from Miami University of Ohio.
Mr. Huennekens is currently chairman, president and chief executive officer of Verb Surgical, which he joined in August 2015. Previously, Mr. Huennekens served as president and chief executive officer of Volcano Corporation from its start-up in 2002, through its IPO in 2006, and to its eventual sale to Royal Philips in 2015. Prior to his work at Volcano, Mr. Huennekens served as president and chief executive officer of Digirad Corporation, a diagnostic imaging solutions provider. Mr. Huennekens is a board member and past chairman of the Medical Device Manufacturer’s Association (MDMA). He graduated magna cum laude with a Bachelor of Science in Business Administration from the University of Southern California in 1986 and earned his Masters of Business Administration from the Harvard Business School in 1991.
Dr. Henry A. McKinnell Jr.
Dr. McKinnell retired as Chairman and CEO of Pfizer Inc. in 2006. His 35 years with the company included the positions of President of Pfizer Asia, President of Pfizer’s medical devices group, President of Pfizer Pharmaceuticals Group, and Chief Financial Officer.
Dr. McKinnell currently serves as the Chairman of the Board of Moody’s Corporation and Chairman of the Board of the Accordia Global Health Foundation. His previous directorships include ExxonMobil Corporation, John Wiley & Sons, Optimer Pharmaceuticals, Inc., Emmaus Life Sciences, Inc., and Angiotech Pharmaceuticals, Inc.
Previously, Dr McKinnell chaired the Business Roundtable, an association of Chief Executive Officers leading U.S. companies with $7 trillion in annual revenues, the Health Industry Manufacturers Association (now known as AdvaMed), the Pharmaceutical Research and Manufacturers of America, the Food and Drug Law Institute, Stanford University Graduate School of Business Advisory Council, and the Connecticut Science Center. Dr. McKinnell also served as Vice Chairman of the World Economic Forum.
Dr. McKinnell has received numerous awards, including the Grand Cordon of the Order of the Rising Sun, Japan’s highest award other than to members of the Imperial Family and heads of state.
Aditya Puri has served as a member of our board of directors since February 2015. Mr. Puri has served as an Investments Director at Xeraya Capital, which is responsible for life sciences investments for Khazanah Nasional Berhad, since October 2012. Previously, he was a Director in Khazanah Nasional’s Life Sciences unit since November 2011, which was responsible for Khazanah’s life sciences investments. Prior to that, Mr. Puri consulted part time in the greater Boston area for various healthcare and cleantech startups affiliated with Harvard University and Massachusetts Institute of Technology, or MIT, from 2009 to 2011. Mr. Puri also served as Managing Director of global development at Salary.com from July 2007 to April 2008. Mr. Puri was at the Yankee Group, a global technology research and consulting company, from September 2000 to March 2007, finishing his tenure as a Vice-President and member of the leadership team. Between March 1997 and April 2000, he was at Boston Scientific, a Fortune 500 medical device manufacturer. Mr. Puri serves on several boards of directors of private companies in the investment and healthcare fields. Mr. Puri has a B.S. from the University of Southern Maine and received an M.B.A. from the MIT Sloan School of Management. We believe Mr. Puri is qualified to serve on our board of directors because of his extensive experience in life sciences investment and growth.
D. Keith Grossman
Mr. Grossman previously served as the President, Chief Executive Officer and Director for Thoratec Corporation through its $3.4 billion acquisition by St. Jude Medical (now Abbott Laboratories, NYSE: ABT) in 2016. From 2011 to 2013, Mr. Grossman served as President, Chief Executive Officer and Director for Conceptus, Inc., where he led its turnaround and acquisition by Bayer Healthcare in 2013. From 2007 to 2011, Mr. Grossman served as a Managing Director with the Texas Pacific Group, a private equity firm, in their healthcare investment team. Mr. Grossman currently serves as a director for Vyaire, Inc., Outset Medical, Inc. and Therox, Inc., and has previously served as a director for Thoratec Corporation, Conceptus, Inc., ZELTIQ Aesthetics, Inc., Intuitive Surgical, Inc., Kyphon, Inc. and a number of privately held medical device companies. Mr. Grossman received a Bachelor of Science in Life Sciences from the Ohio State University and a Master in Business Administration from Pepperdine University.
Brian K. Roberts
Brian K. Roberts previously served as the Chief Operating and Financial Officer of Avedro, the leader in corneal cross-linking science, which recently completed a $32 million equity financing. Prior to Avedro, Roberts served as CFO for Insulet Corporation. During his time at Insulet, the tubeless insulin pump technology company grew from approximately $30 million to nearly $300 million in revenue, achieved operating profitability, and increased its market capitalization to over $2 billion.
Previously, Roberts served as CFO for Jingle Networks, a leader in mobile voice-ad services that was acquired by Marchex, Inc., and as CFO for Digitas, which was sold for $1.3 billion to Publicis Groupe. He holds a Bachelor of Science in Accounting and Finance from Boston College, is a Certified Public Accountant, and served as an auditor with Ernst & Young LLP.
Theodore T. Wang, Ph.D.
Theodore T. Wang, Ph.D. has served as a member of our board of directors since January 2017. Dr. Wang currently serves as the Chief Investment Officer of Puissance Capital Management, of which he was a founder, since January 2015. Prior to that, Dr. Wang was a Partner of Goldman, Sachs & Co. (“Goldman”), which he joined in 1996 and with which he served in many leadership positions, mostly recently as Co-Head of U.S. Equities Trading and Global Co-Head of One Delta Trading and a member of the Goldman Sachs Risk Committee. Prior to joining Goldman, Dr. Wang co-founded Xeotron Corp., a company specializing in DNA biochips in Texas. Dr. Wang holds a Ph.D. in Physics from the University of Minnesota, an M.B.A. from the University of Texas, Austin, and a B.S. from Fudan University, China. We believe Dr. Wang is qualified to serve on our board of directors because of his prior investment and leadership experience in the life science industry.